12 Most Profitable Cheap Stocks to Buy Right Now

10. Gilead Sciences, Inc. (NASDAQ:GILD)

Forward P/E: 14.88

Profit Margin: 30.99%

Net Income Available to Common (TTM): $9.22 Billion

Number of Hedge Fund Holders: 77

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most profitable cheap stocks to buy right now. On June 30, Morgan Stanley kept its Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) and maintained its price target of $168.

The research firm’s positive view is based on a number of factors, including the company’s growth outlook and the Yeztugo launch trajectory. Morgan Stanley sees Yeztugo as a key driver of the company’s growth in the medium term. Gilead Sciences, Inc. (NASDAQ:GILD) has raised its 2026 sales guidance for Yeztugo.

Earlier, on June 15, Gilead Sciences, Inc. (NASDAQ:GILD) announced that the US Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for a 300 mg tablet version of Yeztugo (lenacapavir). The company is seeking approval for the drug as a potential once-weekly (QW) oral formulation for the prevention of HIV as pre-exposure prophylaxis (PrEP). The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of February 2, 2027.

Lenacapavir tablets are already approved as part of the Yeztugo treatment regimen for an initial loading dose and as a bridge therapy when the every-six-month injections are delayed. If the new application is approved, once-weekly oral Yeztugo would become the first long-acting oral PrEP treatment.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company focused on advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation.